Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors

PURPOSE: Vorolanib is a multi-target tyrosine kinase inhibitor with anti-angiogenic properties. This study aimed to evaluate the tolerability, safety and efficacy of vorolanib when added to checkpoint inhibitors (CPIs) in patients with advanced solid tumors. METHODS: We conducted a phase 1b study of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagegni, Nusayba A., Park, Haeseong, Kraft, Katlyn, O-Toole, Maura, Gao, Feng, Waqar, Saiama N., Ratner, Lee, Morgensztern, Daniel, Devarakonda, Siddhartha, Amin, Manik, Baggstrom, Maria Q., Liang, Chris, Selvaggi, Giovanni, Wang-Gillam, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956523/
https://www.ncbi.nlm.nih.gov/pubmed/35247086
http://dx.doi.org/10.1007/s00280-022-04406-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956523/
https://www.ncbi.nlm.nih.gov/pubmed/35247086
http://dx.doi.org/10.1007/s00280-022-04406-6

Ejemplares similares